Finch Therapeutics Group Inc (FNCH)
2.30
+0.38
(+19.79%)
USD |
NASDAQ |
May 20, 14:32
Finch Therapeutics Group Cash from Investing (TTM): 1.341M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.341M |
| December 31, 2023 | 1.327M |
| September 30, 2023 | 1.225M |
| June 30, 2023 | 0.877M |
| March 31, 2023 | -1.287M |
| December 31, 2022 | -2.182M |
| September 30, 2022 | -4.133M |
| Date | Value |
|---|---|
| June 30, 2022 | -6.169M |
| March 31, 2022 | -8.006M |
| December 31, 2021 | -15.92M |
| September 30, 2021 | -16.06M |
| June 30, 2021 | -13.92M |
| March 31, 2021 | -11.38M |
| December 31, 2020 | -2.633M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-16.06M
Minimum
Sep 2021
1.341M
Maximum
Mar 2024
-5.495M
Average
-3.383M
Median
Cash from Investing (TTM) Benchmarks
| ACADIA Pharmaceuticals Inc | -174.56M |
| Vanda Pharmaceuticals Inc | -217.57M |
| Sage Therapeutics Inc | 387.48M |
| BioSig Technologies Inc | -0.186M |
| Palisade Bio Inc | -- |